Vol 87, No 1 (2016)
Review paper
Hormone replacement therapy and cardio-vascular disease
Maciej Lesiak, Ropacka-Lesiak Mariola, Natalia Podkowa
DOI: 10.17772/gp/61022
·
·
Ginekol Pol 2016;87(1):59-64.
Vol 87, No 1 (2016)
REVIEW PAPERS Gynecology
Abstract
The results of large randomized trials such as the Women's Health Initiative (WHI), Heart and Estrogen / Progestin Replacement Study (HERS) or Estrogen Replacement and Atherosclerosis Study (ERAS) as well as the Million Women Study (MWS) which does not meet criteria RCT, concerning, among others the impact of HRT on breast cancer risk, thromboembolism, or the aging processes in the central nervous system caused the recent big confusion in the medical community , causing distrust about the safety and advisability of HRT in menopausal women. The paper presents an overview of the available, current literature on HRT. It was found that HRT should not be used in both primary and secondary prevention of coronary heart disease Great expectations was associated with an earlier initiation of therapy, before the advent of atherosclerosis - but there is currently no conclusive data about its role in the primary prevention of coronary disease. Oral HRT increases the risk of thromboembolic events - that is why you should prefer the form of a transdermal. HRT may increase the risk of ischemic stroke (but early initiation of therapy does not increase the risk of stroke) and should not be used in the primary prevention of stroke.
Abstract
The results of large randomized trials such as the Women's Health Initiative (WHI), Heart and Estrogen / Progestin Replacement Study (HERS) or Estrogen Replacement and Atherosclerosis Study (ERAS) as well as the Million Women Study (MWS) which does not meet criteria RCT, concerning, among others the impact of HRT on breast cancer risk, thromboembolism, or the aging processes in the central nervous system caused the recent big confusion in the medical community , causing distrust about the safety and advisability of HRT in menopausal women. The paper presents an overview of the available, current literature on HRT. It was found that HRT should not be used in both primary and secondary prevention of coronary heart disease Great expectations was associated with an earlier initiation of therapy, before the advent of atherosclerosis - but there is currently no conclusive data about its role in the primary prevention of coronary disease. Oral HRT increases the risk of thromboembolic events - that is why you should prefer the form of a transdermal. HRT may increase the risk of ischemic stroke (but early initiation of therapy does not increase the risk of stroke) and should not be used in the primary prevention of stroke.
Keywords
cardiovascular disease, estrogens, HTZ
Title
Hormone replacement therapy and cardio-vascular disease
Journal
Ginekologia Polska
Issue
Vol 87, No 1 (2016)
Article type
Review paper
Pages
59-64
Page views
1258
Article views/downloads
4334
DOI
10.17772/gp/61022
Pubmed
27306470
Bibliographic record
Ginekol Pol 2016;87(1):59-64.
Keywords
cardiovascular disease
estrogens
HTZ
Authors
Maciej Lesiak
Ropacka-Lesiak Mariola
Natalia Podkowa
About this article